Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 145-152 , March 2010

Update on Recent Developments in the Therapy of Differentiated Thyroid Cancer

  • Marcus Middendorp, MD
    • ,
  • Frank Grünwald, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Frank Grünwald, MD, Department of Nuclear Medicine, Johann Wolfgang Goethe University Medical School, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

References 

  1. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: A review of the literature. Q J Nucl Med Mol Imaging. 2006;50:78–87
  2. Mallick UK, Charalambous H. Current issues in the management of differentiated thyroid cancer. Nucl Med Commun. 2004;25:873–881
  3. Biersack HJ, Grünwald F. Thyroid Cancer. (ed 2). New York: Springer; 2005;
  4. Sclabas GM, Staerkel GA, Shapiro SE, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg. 2003;186:702–709
  5. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–142
  6. Passler C, Scheuba C, Asari R, et al. Importance of tumour size in papillary and follicular thyroid cancer. Br J Surg. 2005;92:184–189
  7. Shaha A. Selective surgical management of well-differentiated thyroid cancer. Ann NY Acad Sci. 2008;1138:58–64
  8. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–381
  9. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid. 2007;17:1085–1092
  10. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: A surgical perspective. Cancer Treat Rev. 2005;31:423–438
  11. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period. Surgery. 2008;144:980–987
  12. D'Avanzo A, Treseler P, Ituarte PH, et al. Follicular thyroid carcinoma: Histology and prognosis. Cancer. 2004;100:1123–1129
  13. Delbridge L, Parkyn R, Philips J, et al. Minimally invasive follicular thyroid carcinoma: Completion thyroidectomy or not?. ANZ J Surg. 2002;72:844–845
  14. Brennan MD, Bergstralh EJ, van Heerden JA, et al. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1991;66:11–22
  15. Furlan JC, Bedard YC, Rosen IB. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg. 2004;198:341–348
  16. Demidchik YE, Demidchik EP, Reiners C, et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg. 2006;243:525–532
  17. Thompson GB, Hay ID. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg. 2004;28:1187–1198
  18. Gingalewski CA, Newman KD. Seminars: Controversies in the management of pediatric thyroid malignancy. J Surg Oncol. 2006;94:748–752
  19. Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: Does it alter the extent of surgery versus well-differentiated thyroid cancer?. World J Surg. 2007;31:916–923
  20. Dralle H, Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab. 2008;22:971–987
  21. Ito Y, Jikuzono T, Higashiyama T, et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg. 2006;30:1821–1828
  22. Vorländer C, Lienenlüke RH, Wahl RA. Lymph node dissection in papillary and follicular thyroid cancer. Chirurg. 2008;79:564–570
  23. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803
  24. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–1959
  25. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–3676
  26. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?. Surgery. 1998;124:958–964
  27. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–260
  28. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692–700
  29. Mazzaferri EL. A randomized trial of remnant ablation—In search of an impossible dream?. J Clin Endocrinol Metab. 2004;89:3662–3664
  30. Sawka AM, Rotstein L, Brierley JD, et al. Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. Thyroid. 2007;17:1235–1242
  31. Hackshaw A, Harmer C, Mallick U, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab. 2007;92:28–38
  32. Jarzab B, Handkiewicz-Junak D, Wloch J, et al. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review. Endocr Relat Cancer. 2005;12:773–803
  33. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer—A quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med. 1992;33:1132–1136
  34. Lassmann M, Hänscheid H, Chiesa C, et al. EANM Dosimetry Committee: Series on standard operational procedures for pre-therapeutic dosimetry I: Blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405–1412
  35. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899
  36. Menzel C, Grünwald F, Schomburg A, et al. “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med. 1996;37:1496–1503
  37. Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2001;86:1568–1573
  38. Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer. 2008;15:37–49
  39. McWilliams RR, Giannini C, Hay ID, et al. Management of brain metastases from thyroid carcinoma: A study of 16 pathologically confirmed cases over 25 years. Cancer. 2003;98:356–362
  40. Menzel C, Zaplatnikov K, Diehl M, et al. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun. 2004;25:239–243
  41. Kulkarni K, Van Nostrand D, Atkins F, et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid. 2006;16:1019–1023
  42. Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1999;84:912–916
  43. Sugino K, Ito K, Takami H. Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH. Endocr J. 2006;53:723–728
  44. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–932
  45. Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–654
  46. Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: Prospects and novel uses. Thyroid. 2008;18:509–516
  47. Intenzo CM, Jabbour S, Dam HQ, et al. Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med. 2005;35:257–265
  48. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49:764–770
  49. Haugen BR, Cooper DS, Emerson CH, et al. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid. 2008;18:687–694
  50. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131I administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3542–3546
  51. Risse JH, Grünwald F, Bender H, et al. Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis. Thyroid. 1999;9:1253–1256
  52. Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16:1121–1130
  53. Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer. 2006;13:971–977
  54. Schuck A, Biermann M, Schober O, et al. Strahlentherapie des Schilddrüsenkarzinoms. [German] Onkologe. 2005;11:87–92
  55. Biermann M, Pixberg MK, Schuck A, et al. Multicenter study differentiated thyroid carcinoma (MSDS) (Diminished acceptance of adjuvant external beam radiotherapy). Nuklearmedizin. 2003;42:244–250
  56. Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74:1083–1091
  57. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: A reassessment. Nat Clin Pract Endocrinol Metab. 2005;1:32–40
  58. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: What are the targets?. J Clin Endocrinol Metab. 2008;93:1167–1169
  59. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998;8:737–744
  60. Heemstra KA, Hamdy NA, Romijn JA, et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006;16:583–591
  61. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76–131
  62. Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: A risk adapted approach. J Surg Oncol. 2008;97:712–716
  63. Santini F, Bottici V, Elisei R, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87:4160–4165
  64. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep. 1986;70:405–407
  65. Raue F. Chemotherapy in thyroid cancer: Indications and results [German]. Onkologe. 1997;3:55–58
  66. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999;16:34–41
  67. Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998;39:1903–1906
  68. Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: Final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775–782
  69. Courbon F, Zerdoud S, Bastie D, et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid. 2006;16:1025–1031
  70. Zhang Y, Jia S, Liu Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun. 2007;28:251–255
  71. Tepmongkol S, Keelawat S, Honsawek S, et al. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: A correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid. 2008;18:697–704
  72. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662–669
  73. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148–156
  74. Coelho SM, Carvalho DP, Vaisman M. New perspectives on the treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2007;51:612–624
  75. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–4719
  76. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42
  77. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol. 2008;26:4708–4713
  78. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18:317–323
  79. Spitzweg C. Gene therapy in thyroid cancer. Horm Metab Res. 2009;41:500–509
  80. Kohlfuerst S, Igerc I, Gallowitsch HJ, et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid. 2006;16:1113–1119
  81. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab. 2006;17:19–25
  82. Iten F, Muller B, Schindler C, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: Long-term results of a phase 2 clinical trial. Cancer. 2009;115:2052–2062
  83. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2201–2204

PII: S0001-2998(09)00104-4

doi: 10.1053/j.semnuclmed.2009.10.006

Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 145-152 , March 2010

Article Tools

* Image Usage & Resolution